SCHEMBL3857572

SCHEMBL3857572

CCCN(C)c1cc(C(=O)OC)cc(Cl)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.43
KDM4E B2RXH2 7/20 0.41
LMNA P02545 3/20 0.40
HCAR3 P49019 1/20 0.40
MAPT P10636 2/20 0.39
CNR1 P21554 1/20 0.38
HTT P42858 2/20 0.38
POLB P06746 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
HPGD P15428 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
HSD17B10 Q99714 1/20 0.37
MEN1 O00255 1/20 0.37
XBP1 P17861 1/20 0.37
KMT2A Q03164 1/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA7 P43166 1/20 0.37
CA9 Q16790 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3350040 0.92 ALDH1A1 (0.41) ALDH1A1KDM4ELMNAMAPTCNR1
SCHEMBL1579300 0.89 ALDH1A1 (0.43) ALDH1A1KDM4ELMNAHTTPOLB
SCHEMBL3720398 0.88 ALDH1A1 (0.42) ALDH1A1KDM4ELMNAHTTPOLB
SCHEMBL5159399 0.83 HCAR3 (0.38) ALDH1A1KDM4ELMNAHCAR3MAPT
SCHEMBL3715004 0.82 ALDH1A1 (0.47) ALDH1A1KDM4ELMNAMAPTHTT
SCHEMBL1816292 0.82 ALDH1A1 (0.40) ALDH1A1KDM4ELMNAMAPTPOLB
SCHEMBL1424831 0.81 KDM4E (0.47) ALDH1A1KDM4ELMNAMAPTHTT
SCHEMBL3855487 0.80 KDM4E (0.39) ALDH1A1KDM4ELMNAHCAR3MAPT
SCHEMBL3858500 0.80 LMNA (0.38) ALDH1A1KDM4ELMNAHCAR3MAPT
SCHEMBL3712465 0.79 SMN1; SMN2 (0.55) ALDH1A1KDM4ELMNAMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7618978-B2 Amides as BACE inhibitors ELI LILLY AND COMPANY (US) 2009-11-17 US disclosed
US-7585885-B2 Pyrrolidine derivatives useful as BACE inhibitors ELI LILLY AND COMPANY (US) 2009-09-08 US disclosed
US-20070225372-A1 Amides as Bace Inhibitors ELI LILLY AND COMPANY 2007-09-27 US disclosed
US-20070213331-A1 PYRROLIDINE DERIVATIVES USEFUL AS BASE INHIBITORS ELI LILLY AND COMPANY 2007-09-13 US disclosed
EP-1740575-A2 PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS ELI LILLY AND COMPANY (US) 2007-01-10 EP disclosed
EP-1740573-A1 AMIDES AS BACE INHIBITORS ELI LILLY AND COMPANY (US) 2007-01-10 EP disclosed
WO-2005108391-A1 AMIDES AS BACE INHIBITORS ELI LILLY AND COMPANY (US) 2005-11-17 WO disclosed
WO-2005108358-A2 PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS ELI LILLY AND COMPANY (US) 2005-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225372-A1 Amides as Bace Inhibitors BACE2, BACE1, APP ALDH1A1 661/4885KDM4E 453/4885LMNA 1677/4885
US-20070213331-A1 PYRROLIDINE DERIVATIVES USEFUL AS BASE INHIBITORS BACE1, BACE2, PSEN1 ALDH1A1 1523/4885KDM4E 1975/4885LMNA 2877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.